{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.rybrevant:2 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.rybrevant%3A2",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003747,
    "timestamp_received": "2026-04-24T03:10:16.915436+00:00Z",
    "timestamp_returned": "2026-04-24T03:10:16.919183+00:00Z",
    "trace_id": "f07bb69d-c373-4ae3-bdbe-74c96cb9468a"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.rybrevant:2",
      "indication": "Rybrevant is indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).",
      "initial_approval_date": "2024-09-13",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rybrevant-h-c-005454-ii-0011-epar-assessment-report-variation_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).",
      "raw_biomarkers": "EGFR Exon 19 deletions or Exon 21 L858R",
      "raw_cancer_type": "Non-small cell lung cancer",
      "raw_therapeutics": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.rybrevant",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Rybrevant (amivantamab) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2025. Accessed September 5, 2025.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant",
          "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Janssen-Cilag International N.V.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Rybrevant",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "amivantamab",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2022-02-01",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-07-18",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}